Foresee Pharmaceuticals Co (6576) Fair Value & Analysis

Healthcare · TW · Market cap 12.9B TWD

Below-average quality, screening 56% undervalued on our models.

What matters now

• The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain.
• The price is below even our cautious bear case (81.79 TWD). The market is more pessimistic than our downside scenario.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (81.79 TWD to 155.18 TWD) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

60‑month range 57.90 TWD – 135.00 TWD · fair‑value band 81.79 TWD – 155.18 TWD · the 79.60 TWD price screens below the 124.14 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Foresee Pharmaceuticals Co (6576) currently trades at 79.60 TWD, while our model-based Fair Value estimate is 124.14 TWD, implying the stock looks roughly 56.0% undervalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Over the trailing twelve months, Foresee Pharmaceuticals Co generated revenue of 401M TWD at a net margin of -45.7%. Revenue declined 27.3% year over year. It earns a return on equity of -13.5%. Fundamentals as of Jul 21, 2026

Our scenario range runs from 81.79 TWD (bear case) to 155.18 TWD (bull case); at 79.60 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 15% below its 52-week high and 29% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 56%, 6576 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and …

Full company description

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. The company was incorporated in 2013 and is headquartered in Taipei, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Foresee Pharmaceuticals Co reported revenue of 431M TWD in FY2025 versus 226M TWD in FY2021, a compound +17.5%/yr. Reported net income was −883M TWD in FY2025.

Watch 6576: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 623 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.